ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2596

The Contribution of Left Heart Disease in Patients with Systemic Sclerosis-associated Pulmonary Hypertension Having Normal Pulmonary Artery Wedge Pressure

Yoshioki Yamasaki1, Kanako Suzuki 1, Keiichi Sakurai 2, Yusa Asari 1, Hidehiro Yamada 3 and Kimito Kawahata 2, 1Rheumatology and Allergology, St. Marianna University School of Medicine, Kawasaki, Japan, 2Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan, 3Center for Rheumatic diseases, Seirei Yokohama Hospital, Kawasaki, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: pulmonary complications and heart disease, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with systemic sclerosis (SSc) complicates variety of cardiopulmonary diseases which can result in pulmonary hypertension (PH). The types of PH are usually classified by the result of right heart catheterization (RHC) based on values of mean pulmonary arterial pressure (mPAP), pulmonary artery wedge pressure (PAWP), and pulmonary vascular resistance (PVR): Group 1 as mPAP >20mmHg, PAWP ≤15mmHg, and PVR ≥3WU; Group 2 as mPAP >20mmHg, PAWP >15mmHg, and PVR < 3WU. However, by this classification, patients with PH having normal PAWP (≤15mmHg) and normal PVR (< 3 WU) are categorized as neither Group 1 PH nor Group 2 PH and have a possible contribution of left heart disease (LHD). We therefore examined whether LHD is contributing among SSc-PH patients with such RHC results.

Methods: We retrospectively investigated 43 patients with SSc who were diagnosed as PH by RHC from 2006 through 2018 at our University hospital. Nice classification updated in 2018 was used in the diagnosis and classification of PH. To identify lesions responsible for PH, inspections with cardiac echocardiography, cardiac MRI, and myocardial scintigraphy were conducted.

Results: The mean age of the enrolled 43 patients was 66 (11) year-old, 88% of them were female. Twenty-one percent of the patients had diffuse cutaneous SSc. Mean follow-up periods were 56 (33) months.  Of the 43, 17 (40%) of the patients had severe interstitial lung disease with % forced vital capacity ≤70% (Group 3). Among the rest of 26 patients, 5 (19%) had PAWP >15mmHg (Group 2). Of the remaining 21 patients, only 10 patients (48%) had PVR ≥3 WU and was classified as Group 1 and another 11 had PAWP ≤15mmHg and PVR < 3WU. Among them, 9 patients (82%) showed less than 7 of diastolic pressure gradient obtained from RHC, indicating the presence of postcapillary PH. Among them, 6 patients (55%) had an elevation of E/e’ and/or left atrial volume index (LAVI), suggesting left diastolic dysfunction by cardiac echocardiography. Myocardial damage was detected by cardiac MRI [n = 6 (55%)] or myocardial scintigraphy [n = 6 (55%)]. Based on the results, 5 patients were diagnosed as precapillary PH and another 5 as postcapillary PH in addition to 5 with PAWP >15mmHg [in total, 10 / 43 (23%) with SSc-PH had LHD-associated PH]. The diagnosis was undetermined in one patient who had mixed characteristics of pre- and postcapillary PH. Pulmonary vasodilators were introduced in 5 patients who were clinically diagnosed as precapillary PH while diuretics and/or antihypertensive drugs were introduced in another 4 diagnosed as postcapillary PH. One patient died from PAH during the mean follow-up.

Conclusion: Since significant number of patients may have LHD, particularly diastolic dysfunction-associated PH even among SSc patients with normal PAWP as well as those with PAWP >15mmHg, careful diagnosis and therapeutic intervention with pulmonary vasodilator are required in this patient population. Longitudinal follow up will be needed to study the impact of the LHD on the survival.


Disclosure: Y. Yamasaki, None; K. Suzuki, None; K. Sakurai, None; Y. Asari, None; H. Yamada, None; K. Kawahata, None.

To cite this abstract in AMA style:

Yamasaki Y, Suzuki K, Sakurai K, Asari Y, Yamada H, Kawahata K. The Contribution of Left Heart Disease in Patients with Systemic Sclerosis-associated Pulmonary Hypertension Having Normal Pulmonary Artery Wedge Pressure [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-contribution-of-left-heart-disease-in-patients-with-systemic-sclerosis-associated-pulmonary-hypertension-having-normal-pulmonary-artery-wedge-pressure/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-contribution-of-left-heart-disease-in-patients-with-systemic-sclerosis-associated-pulmonary-hypertension-having-normal-pulmonary-artery-wedge-pressure/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology